为成人和老年患者开发和优化瓜伊芬尼持续释放迷你片
Mahshid Samadi1, Mitra Jelvehgari2, Sara Salatin3
1Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
Therapeutic delivery
|October 3, 2024
概括
用卡纳乌巴和乙烯纤维素制成的瓜伊费内辛持续释放迷你片. 优化的迷你平板显示出出色的药物释放特征,为成人和老年人提供了有希望的替代品.
科学领域:
- 制药科学 制药科学
- 药物输送系统 药物输送系统
背景情况:
- 瓜伊芬素通常用于咳和感冒症状.
- 传统配方可能需要频繁的剂量.
- 持续释放剂型的开发可以改善患者的服药性和治疗疗效.
研究的目的:
- 为了制定和优化持续释放 (SR) 的小药片的瓜伊芬尼辛.
- 评估卡纳乌巴和乙烯纤维素对药物释放的影响.
主要方法:
- 采用化颗粒技术,以不同比例的卡纳乌巴制备瓜伊芬尼辛颗粒.
- 颗粒进一步用乙烯基纤维素进行了修改.
- 迷你片被压缩并以物理化学特性和体外药物释放为特征.
主要成果:
- 用1:6的卡纳乌巴与药物比率配制的迷你片显示出最佳的物理化学特性.
- 这些优化的迷你片在8小时内释放了大约100.03%的瓜伊芬尼辛.
- 乙纤维素在控制迷你片中的药物释放速度方面被证明是有效的.
结论:
- 开发的瓜伊芬持续释放迷你药片代表了传统配方的有希望的替代品.
- 这种新型剂型适用于成人和老年人群.
- 该研究强调了卡纳乌巴和乙烯纤维素在设计可控释放药物递送系统中的潜力.
相关概念视频
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
Modified-Release Drug Delivery Systems: Influencing Factors
Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...
Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...


